MAP Patient Access Limited

We are thrilled to share the news that MAP have joined forces with AxTalis to create a new group focussing on accelerating patient access across European markets.   Read more in our press release: https://lnkd.in/eDQnnHXA #patientaccess

We are growing our regulatory affairs team with the addition of Sam Bryant as our new Regulatory Affairs Manager. Our team can support clients in all regulatory matters throughout the lifecycle of a healthcare solution, such as: - Regulatory Affairs (RA) strategy - European Medicines Agency (EMA) Prime, ODD, Scientific advice, PIP - New Marketing Authorisation Applications (Centralised, Mutual Recognition, Decentralised or National Procedures) - Regulatory life cycle management - Chemistry, Manufacturing and Controls (CMC) expertise - Medical device certification Get in touch now via our company page to find out more about our regulatory affairs offering.   Please join us in extending a warm welcome to Sam! #TeamSpotlight #RegulatoryAffairs #Welcome

Understanding who your primary stakeholders are is a vital first step for effective market access strategies. Our Head of Policy & Public Affairs Nisha Tailor takes a look at who they are and explores some best practices for engaging with them.   Dive into our carousel to learn about engaging with HTA bodies, patient advocacy groups and more.   #stakeholderengagement #marketaccess #blog

Mark your calendars for ISPOR Europe 2024 in Barcelona! 🗓️   In 5 weeks' time our team will attend ISPOR—The Professional Society for Health Economics and Outcomes Research Europe. We are preparing to join the global HEOR community, and are looking forward to presenting some new research posters. Attending will be: - Sven Tops, Chief Market Access Officer - Melanie van Riemsdijk, Director Market Access Benelux - Jo Wallis, Vice President, Early Strategic Advice and Market Access UK/IRE - Maciej Maruszczak, Health Economics, Operational & Data Insights Lead - Monica Ricci, Ph.D., Senior Medical & Market Access Manager - Ben Hendry, Associate Director, Market Access - Praptee Ghimire, Consultant, Value Communication - Xingyao Liu, Consultant, Health Economics and Outcomes Research - Daniel Harrop, Senior Consultant, Health Economics and Outcomes Research - Kristof Theys, Health Economics and Data Science Manager   If you would like to meet up with our team, please feel free to reach out to them directly via LinkedIn direct message. 🤝   #ISPOR #ISPOREurope #HealthEconomics

Preparing for a product launch in the UK?   Our resource is ready to guide you through the entire process! With deep expertise in market access and over 200 HTA submissions, we can help you craft a strategy for launch success.   Grab our essential 12-point checklist here: https://lnkd.in/ezviuJpu   #UKMAChecklist #UK #HealthTechnology

Meet the panel for our upcoming webinar 🔔   Our next webinar aims to reflect on lessons learned from engaging with patient advocacy groups in the HTA process to better understand the pitfalls and barriers with rare disease patients and patient advocacy groups; as well as exploring the opportunities to amplify the influential voice of patients. Our expert panel includes: - Sujan Sivasubramaniyam, Head of Medical Affairs and Patient Advocacy, UK & Ireland at CSL Behring - Ellie Davies, Policy Analyst at Cystic Fibrosis Trust - Claire Blaney, Country Manager, Ireland at the MAP Group This webinar will explore the following questions: - How and when might patients, caregivers and patient advocacy groups be involved in NICE, SMC and NCPE HTA processes? - How can the biopharma industry engage with patients, caregivers and patient advocacy groups on upcoming HTAs, whilst meeting industry codes of practice? - How do patients and patient advocacy groups want to engage with biopharma companies? What is best practice and what should be avoided?   - What are patients’, caregivers’ and patient advocacy groups’ experiences of participating in HTA consultations and committees? There is still time to register for your free place here: https://lnkd.in/ewzUBSKy #patientadvocacy #HTA #patientengagement

Let’s connect at the World Orphan Drug Congress 2024   Frank Vanderdonck and Sven Tops will be representing the MAP Group at the upcoming congress in Barcelona. They would be happy to meet if you would like to discuss your current challenges, or how we can support your organisation from regulatory approval, HTA, pricing and reimbursement through to launch of orphan drugs.   #OrphanDrugCongress2024 #WODC

We are inviting our members to comment on the European Commission’s JSC Consultation. The European Commission (EC) has announced a consultation on Joint Scientific Consultations (JSC) by 29 October 2024. JSCs are a core part of the new EU Health Technology Assessment Regulation (EU HTAR) , enabling early engagement between health technology developers and the EU HTA as well as the European Medicines Agency (EMA) to streamline the preparation for joint clinical assessments (JCAs). MAP x AxTalis will be responding to the consultation and ask our members to provide their feedback and insights on the proposed JSC process – look out for an email with further details. #JSC #EUHTA #JCA 

Oncology and ATMP products will be required to go through the EU HTA from January 2025. With 3 months to go, we are continuing to advise our clients on steps they can take to prepare. An important first step is to familiarise yourself with the key milestones of the EU JCA process ⬇ If you would like to discuss any of these points in more detail with our consultancy teams, please do reach out 📞   #EUHTA #JCA #HTA

World Orphan Drug Congress 2024 - will we see you there? Frank Vanderdonck and Sven Tops will be heading to World Orphan Drug Congress Europe in Barcelona in a couple of weeks. Do reach out to them if you would like to discuss how MAP x AxTalis can support your organisation to give orphan drugs the best chance of reaching patients. #orphandrug #WODC